» Articles » PMID: 35711577

Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review

Overview
Specialty Psychiatry
Date 2022 Jun 17
PMID 35711577
Authors
Affiliations
Soon will be listed here.
Abstract

Schizophrenia spectrum disorders (SSD) are traditionally diagnosed and categorized through clinical assessment, owing to their complex heterogeneity and an insufficient understanding of their underlying pathology. However, disease progression and accurate clinical diagnosis become problematic when differentiating shared aspects amongst mental health conditions. Hence, there is a need for widely accessible biomarkers to identify and track the neurobiological and pathophysiological development of mental health conditions, including SSD. High-throughput omics applications involving the use of liquid chromatography-mass spectrometry (LC-MS) are driving a surge in biological data generation, providing systems-level insight into physiological and pathogenic conditions. Lipidomics is an emerging subset of metabolomics, largely underexplored amongst the omics systems. Lipid profiles in the brain are highly enriched with well-established functions, including maintenance, support, and signal transduction of neuronal signaling pathways, making them a prospective and exciting source of biological material for neuropsychiatric research. Importantly, changes in the lipid composition of the brain appear to extend into the periphery, as there is evidence that circulating lipid alterations correlate with alterations of psychiatric condition(s). The relative accessibility of fluid lipids offers a unique source to acquire a lipidomic "footprint" of molecular changes, which may support reliable diagnostics even at early disease stages, prediction of treatment response and monitoring of treatment success (theranostics). Here, we summarize the latest fluid lipidomics discoveries in SSD-related research, examining the latest strategies to integrate information into multi-systems overviews that generate new perspectives of SSD-related psychosis identification, development, and treatment.

Citing Articles

An exploratory study of metabolomics in endogenous and cannabis-use-associated psychotic-like experiences in adolescence.

Kurkinen K, Karkkainen O, Lehto S, Luoma I, Kraav S, Kivimaki P Transl Psychiatry. 2024; 14(1):466.

PMID: 39511135 PMC: 11543670. DOI: 10.1038/s41398-024-03163-9.


Identifying plasma metabolic characteristics of major depressive disorder, bipolar disorder, and schizophrenia in adolescents.

Yin B, Cai Y, Teng T, Wang X, Liu X, Li X Transl Psychiatry. 2024; 14(1):163.

PMID: 38531835 PMC: 10966062. DOI: 10.1038/s41398-024-02886-z.


Untargeted Plasma Metabolomic Profiling in Patients with Depressive Disorders: A Preliminary Study.

Chernonosov A, Mednova I, Levchuk L, Mazurenko E, Roschina O, Simutkin G Metabolites. 2024; 14(2).

PMID: 38393002 PMC: 10890195. DOI: 10.3390/metabo14020110.

References
1.
Liu Y, Song X, Liu X, Pu J, Gui S, Xu S . Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: A targeted metabolomics study. Psychiatry Clin Neurosci. 2021; 75(4):138-144. DOI: 10.1111/pcn.13194. View

2.
. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511(7510):421-7. PMC: 4112379. DOI: 10.1038/nature13595. View

3.
Alves M, Lamichhane S, Dickens A, McGlinchey A, Ribeiro H, Sen P . Systems biology approaches to study lipidomes in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2020; 1866(2):158857. DOI: 10.1016/j.bbalip.2020.158857. View

4.
Pettegrew J, Keshavan M, Panchalingam K, Strychor S, Kaplan D, Tretta M . Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 1991; 48(6):563-8. DOI: 10.1001/archpsyc.1991.01810300075011. View

5.
Wood P . Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology. 2013; 39(1):24-33. PMC: 3857645. DOI: 10.1038/npp.2013.167. View